CMPX vs PFE · $367.4M cap vs P/E 20, rev $62.58B
Compass Therapeutics Inc. (CMPX) versus Pfizer Inc (PFE) — a side-by-side from cached financials, not a winner call.
Compass Therapeutics Inc. (CMPX) is a biotechnology company listed on US.
Pfizer Inc (PFE) is a drug manufacturers - general company listed on NYSE. It is led by Albert Bourla.
CMPX does not have a complete income-statement cache yet.
Latest reported PFE revenue for 2025-12-31 was $62.58B. Net income was $7.77B. Revenue was down 1.6% from 2024-12-31 to 2025-12-31. PFE currently screens at market cap $147.73B and trailing P/E 19.8.
CMPX currently screens at market cap $367.4M. PFE currently screens at market cap $147.73B and trailing P/E 19.8.
Not investment advice. Open the CMPX and PFE stock pages for the full models.
Not investment advice.